Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Modafinil - Teva Pharmaceutical Industries

Drug Profile

Modafinil - Teva Pharmaceutical Industries

Alternative Names: AFT-801; Alertec; Attenace™; CN 801; CRL 40476; Modasamil; Modasonil; Modavigil; Modiodal; Provigil; Sparlon; Vigil

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cephalon
  • Developer Alfresa Pharma Corporation; Lundbeck A/S; Mitsubishi Tanabe Pharma Corporation; Teva Pharmaceutical Industries
  • Class Benzhydryl compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy; Hypersomnia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypersomnia; Narcolepsy
  • No development reported Alzheimer's disease
  • Discontinued Attention-deficit hyperactivity disorder; Parkinson's disease

Most Recent Events

  • 08 Sep 2021 Biomarkers information updated
  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 02 Feb 2017 Alfresa Pharma Corporation completes in a long-term phase III trial for Hypersomnia in Japan before February 2017 (JapicCTI-142615)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top